Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c

by Stelios Karayiannides, Catarina Djupsjö, Jeanette Kuhl, Claes Hofman-Bang, Anna Norhammar, Martin J. Holzmann, Pia Lundman
Published 2021-06-01

Salivary Matrix Metalloproteinase-8 and -9 and Myeloperoxidase in Relation to Coronary Heart and Periodontal Diseases: A Subgroup Report from the PAROKRANK Study (Periodontitis and...

by Nilminie Rathnayake, Anders Gustafsson, Anna Norhammar, Barbro Kjellström, Björn Klinge, Lars Rydén, Taina Tervahartiala, Timo Sorsa, PAROKRANK Steering Group
Published 2015-01-01

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results fr...

by Giulia Ferrannini, Dirk De Bacquer, Pieter Vynckier, Guy De Backer, Viveca Gyberg, Kornelia Kotseva, Linda Mellbin, Anna Norhammar, Jaakko Tuomilehto, David Wood, Lars Rydén, EUROASPIRE IV & V Investigators
Published 2021-02-01

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

by Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S. P. Lam, Su-Yen Goh, Chern-En Chiang, Jonathan E. Shaw, Matthew A. Cavender, Navdeep Tangri, Josep Franch-Nadal, Reinhard W. Holl, Marit E. Jørgensen, Anna Norhammar, Johan G. Eriksson, Francesco Zaccardi, Avraham Karasik, Dianna J. Magliano, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, the CVD-REAL Investigators and Study Group
Published 2021-07-01